Redeye provides an update following CLS’s Q4 2024 report.
Q4 net sales and clean EBIT were broadly in line with consensus.
Q4 NAV beat our estimate... ...driven by valuation increases in private portfolio Fair value increas...
Absolent’s Q4 numbers are well in line with Redeye’s expectations on Group level in terms of sales a...
Luxbright har publicerat Bolagets bokslutskommuniké för år 2024.
Sales -4% vs. ABGSCe (-11% y-o-y), EBIT -24% vs. ABGSCe Weaker orders but improving margins, partly ...
Today, 13.00-13.45, Clinical Laserthermia Systems CEO Dan Mogren and CFO Håkan Rosqvist will present...
Analyst Group inleder idag den 21:e februari 2024 analysbevakning på Cedergrenska AB (”Cedergrenska”...
Sales SEK 432m +3% vs. ABGSCe 419m EBIT better than expected Consensus EBIT estimate revisions likel...
Redeye comments on Binero IT’s H2-24 results. Sales were SEK212m in the second half of the year, rep...
Redeye saw a sales development that was just below our expectations.
Net sales and clean EBIT were close to market consensus (LSEG) in Q4.
We upgrade our Q4 EBIT forecast slightly, due to 18% y/y growth in cargo vessel calls.
Redeyes’ long-term view of Dignitana continues to be positive.
Redeye updates on Better Collective following its Q4-results and guidance for 2025.
